通过血管改变和免疫监测,STING激活可以对抗质母细胞瘤
Justin V Joseph1, Mathilde S Blaavand1, Huiqiang Cai1
1Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Cancer letters
|November 6, 2023
概括
在临床前模型中,通过STING激动剂疗法激活先天免疫系统可以减少质母细胞瘤的进展和延长存活时间. 这种方法增强了细胞毒性T细胞的活性,并破坏了瘤血管系统,这表明了治疗脑瘤的有希望的新途径.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 质母细胞瘤 (GBM) 是一种具有不良预后和有限治疗选择的侵袭性脑瘤.
- 目前的免疫治疗方法,如检查点抑制剂,在GBM中显示出最小的疗效.
- 需要新的策略来加强免疫监测并克服GBM的治疗耐药性.
研究的目的:
- 在临床前的GBM模型中研究长期STING激活的疗效.
- 了解STING激活对瘤免疫和血管化的影响.
- 探索用于增强GBM免疫疗法的组合策略.
主要方法:
- 使用了两种临床前的GBM模型:正体GBM干细胞外移植和CRISPR介导的瘤发生.
- 为长期的先天性免疫激活使用药理学性STING激动剂.
- 评估瘤进展,存活率,T细胞透和特异性,瘤血管结构以及VEGFR/VEGF表达.
主要成果:
- 长期激活STING可以减少质母细胞瘤的进展,并显著延长存活时间.
- 激活STING促进了瘤微环境中的细胞毒性T细胞的招募和激活.
- 长时间的STING激活诱导了瘤缺氧和瘤血管结构的改变,激活了VEGFR信号.
结论:
- 通过STING激动剂的先天性免疫激活可以有效地阻碍质母细胞瘤的发展并增强抗瘤免疫力.
- 单独激活STING就足以引起免疫反应并破坏瘤血管化,而没有与抗PD1.1的协同效应.
- 通过STING激活准先天性免疫力,可能与抗VEGF疗法相结合,是未来GBM治疗的有希望的策略.
相关概念视频
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


